Search Results - Willems, B.E

  • Showing 1 - 4 results of 4
Refine Results
  1. 1
    SOF/VEL/VOX results in high SVR12 rates when administered for 12 weeks in DAA-experienced patients or for 8 Weeks in DAA-naïve patients: an integrated analysis of the POLARIS-1, POLARIS-2, POLARIS-3 and POLARIS-4 studies

    SOF/VEL/VOX results in high SVR12 rates when administered for 12 weeks in DAA-experienced patients or for 8 Weeks in DAA-naïve patients: an integrated analysis of the POLARIS-1, PO... by Roberts, S.K, Cooper, C.L, Lawitz, E, Reddy, K.R, Thompson, A.J, Zeuzem, S, Jacobson, I.M, Ruane, P, Hyland, R.H, Stamm, L.M, Han, L, Brainard, D.M, Bräu, N, Asselah, T, Willems, B.E, Flamm, S, Bourlière, M, Foster, G.R, Gane, E.J, Manns, M, Gordon, S.C, Kowdley, K

    Published in Journal of hepatology
    Get full text
    Items that cite this one
    Article
    Save to List
    Saved in:
  2. 2
    The safety and tolerability of SOF/VEL/VOX for 8 or 12 weeks in >1,000 patients treated in the POLARIS-1, POLARIS-2, POLARIS-3, and POLARIS-4 studies: an integrated analysis

    The safety and tolerability of SOF/VEL/VOX for 8 or 12 weeks in >1,000 patients treated in the POLARIS-1, POLARIS-2, POLARIS-3, and POLARIS-4 studies: an integrated analysis by Manns, M, Gane, E.J, Willems, B.E, Roberts, S.K, Flamm, S, Bourliére, M, Asselah, T, Alric, L, Hyland, R.H, Stamm, L.M, Huang, K.C, Brainard, D.M, Khalili, M, Foster, G.R, Gordon, S.C, Reddy, K.R, Zeuzem, S, Jacobson, I.M, Cooper, C.L, Thompson, A.J, Kowdley, K, Lawitz, E

    Published in Journal of hepatology
    Get full text
    Items that cite this one
    Article
    Save to List
    Saved in:
  3. 3
    SAT-280 - SOF/VEL/VOX results in high SVR12 rates when administered for 12 weeks in DAA-experienced patients or for 8 Weeks in DAA-naïve patients: an integrated analysis of the POLARIS-1, POLARIS-2, POLARIS-3 and POLARIS-4 studies

    SAT-280 - SOF/VEL/VOX results in high SVR12 rates when administered for 12 weeks in DAA-experienced patients or for 8 Weeks in DAA-naïve patients: an integrated analysis of the POL... by Roberts, S.K., Cooper, C.L., Lawitz, E., Reddy, K.R., Thompson, A.J., Zeuzem, S., Jacobson, I.M., Ruane, P., Hyland, R.H., Stamm, L.M., Han, L., Brainard, D.M., Bräu, N., Asselah, T., Willems, B.E., Flamm, S., Bourlière, M., Foster, G.R., Gane, E.J., Manns, M., Gordon, S.C., Kowdley, K.

    Published in Journal of hepatology
    Get full text
    Article
    Save to List
    Saved in:
  4. 4
    SAT-236 - The safety and tolerability of SOF/VEL/VOX for 8 or 12 weeks in >1,000 patients treated in the POLARIS-1, POLARIS-2, POLARIS-3, and POLARIS-4 studies: an integrated analysis

    SAT-236 - The safety and tolerability of SOF/VEL/VOX for 8 or 12 weeks in >1,000 patients treated in the POLARIS-1, POLARIS-2, POLARIS-3, and POLARIS-4 studies: an integrated analy... by Manns, M., Gane, E.J., Willems, B.E., Roberts, S.K., Flamm, S., Bourliére, M., Asselah, T., Alric, L., Hyland, R.H., Stamm, L.M., Huang, K.C., Brainard, D.M., Khalili, M., Foster, G.R., Gordon, S.C., Reddy, K.R., Zeuzem, S., Jacobson, I.M., Cooper, C.L., Thompson, A.J., Kowdley, K., Lawitz, E.

    Published in Journal of hepatology
    Get full text
    Article
    Save to List
    Saved in:

Search Tools: